445 related articles for article (PubMed ID: 9815857)
1. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
2. Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Radiat Oncol Investig; 1998; 6(2):71-80. PubMed ID: 9572683
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
5. [Complete remission of bladder cancer with multiple pulmonary metastases obtained by combined chemotherapy with cis-platinum, adriamycin and cyclophosphamide].
Takigawa H; Odachi M; Kagawa S; Kurokawa K
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1877-9. PubMed ID: 4041165
[TBL] [Abstract][Full Text] [Related]
6. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
8. Modulation of hematologic and immunologic effects of high dose chemotherapy by interleukin-2 in a murine tumor model.
Rinehart JJ; Triozzi PL; Lee MH; Aldrich W; Young D
Mol Biother; 1992 Jun; 4(2):77-82. PubMed ID: 1515098
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
10. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12.
Coughlin CM; Wysocka M; Trinchieri G; Lee WM
Cancer Res; 1997 Jun; 57(12):2460-7. PubMed ID: 9192826
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer.
Soloway MS
Natl Cancer Inst Monogr; 1978 Dec; (49):327-32. PubMed ID: 748788
[TBL] [Abstract][Full Text] [Related]
12. Effect of murine alpha-, beta-, and gamma-interferons in combination with alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on the tumor growth and metastasis of B16 melanoma and Lewis lung carcinoma in mice.
Sunkara PS; Bowlin TL; Rosenberger AL; Fleischmann WR
J Biol Response Mod; 1989 Apr; 8(2):170-9. PubMed ID: 2499664
[TBL] [Abstract][Full Text] [Related]
13. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
Sirotnak FM; Otter GM; Schmid FA
Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
[TBL] [Abstract][Full Text] [Related]
14. Immune regulation of metastasis from in vivo derived syngeneic murine melanoma.
Harning R; Koo GC; Szalay J
Reg Immunol; 1990; 3(2):97-102. PubMed ID: 1965137
[TBL] [Abstract][Full Text] [Related]
15. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic experience of advanced urothelial tract tumors.
Nakada T; Akiya T; Yoshikawa M; Umeda K; Katayama T
Hinyokika Kiyo; 1985 Apr; 31(4):601-6. PubMed ID: 4041118
[TBL] [Abstract][Full Text] [Related]
17. [Effect of combination chemotherapy of nitrosourea MCNU with various anti-tumor agents].
Ninomiya K; Sekido S; Araki T
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1315-23. PubMed ID: 6428326
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
19. Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice.
Mitrus I; Delić K; Wróbel N; Missol-Kolka E; Szala S
Acta Biochim Pol; 2006; 53(2):357-60. PubMed ID: 16733559
[TBL] [Abstract][Full Text] [Related]
20. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.
Nishio S; Yamada N; Ohyama H; Yamanegi K; Nakasho K; Hata M; Nakamura Y; Fukunaga S; Futani H; Yoshiya S; Ueda H; Taniguchi M; Okamura H; Terada N
Cancer Sci; 2008 Jan; 99(1):113-20. PubMed ID: 17949451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
